The St. Louis-Cape Girardeau CCOP is a consortium of six hospitals in two separate health service areas in Eastern Missouri. The group of investigators from the St. Louis Metropolitan area are affiliated with one or more of the four hospitals in the consortium and have worked together for the past six years in cancer treatment research studies. The Cape Girardeau investigators have elected to join the St. Louis group and thereby increase the area of influence of this community clinical Oncology Program. We expect to accrue 125-150 credits for cancer treatment research protocols each year and approximately 50 credits for cancer control studies depending on availability of the latter. We plan to continue to provide high-quality data to the Southwest Oncology Group and the National Surgical Adjuvant Breast Program which are our research bases, utilizing the data management system developed during the past six years. We will also continue our commitment to post-graduate education for the members of this CCOP through discussions at tumor board as well as CCOP sponsored seminars on a variety of cancer topics. In addition, we will work with appropriate community agencies as our cancer control research program develops. In summary, we plan to continue our excellent performance of the past six years in the cancer treatment research arena and add cancer control research studies as they become available. The past experience and abilities of the investigators and the data managers provides a strong base for continuing development of this Community Clinical Oncology Program. The inclusion of two additional community hospitals in a separate service area should further enhance our program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035128-09
Application #
3557541
Study Section
Special Emphasis Panel (SRC (54))
Project Start
1987-06-01
Project End
1994-05-31
Budget Start
1992-06-01
Budget End
1993-05-31
Support Year
9
Fiscal Year
1992
Total Cost
Indirect Cost
Name
St. John's Mercy Medical Center
Department
Type
DUNS #
071958003
City
Saint Louis
State
MO
Country
United States
Zip Code
63141
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7

Showing the most recent 10 out of 108 publications